FETAL FIBRONECTIN IN THE CERVICOVAGINAL FLUID OF WOMEN WITH THREATENED PRETERM LABOR AS A PREDICTOR OF DELIVERY BEFORE 34 WEEKS GESTATION

被引：35

作者：

PARKER, J ^{[1
]}

BELL, R ^{[1
]}

BRENNECKE, S ^{[1
]}

机构：

[1] ROYAL WOMENS HOSP,DEPT PERINATAL MED,MELBOURNE,VIC,AUSTRALIA

来源：

AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY | 1995年 / 35卷 / 03期

关键词：

D O I：

10.1111/j.1479-828X.1995.tb01976.x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Petal fibronectin (fFN) is an extracellular matrix protein found at the junction between fetal and maternal tissue. It has been hypothesized that fFN is released into cervicovaginal fluid prior to the onset of preterm labour and during episodes of threatened preterm labour (TPL). In the present study fFN was present in the cervicovaginal fluid of 31% (11/36) of patients with TPL. The presence of fFN was found to be predictive of delivery prior to 34 weeks' gestation in 36 patients presenting with TPL and intact membranes (sensitivity 100%, specificity 81%). Eleven patients had a positive fFN assay and 5 delivered before 34 weeks (positive predictive value (PPV) 46%). Twenty-five patients had a negative fFN result and none were delivered before 34 weeks (negative predictive value (NPV) 100%). Patients presenting with TPL who are fFN positive would be ideal candidates for intervention trials of tocolytics. It may be possible to delay or avoid immediate tocolysis and interhospital transfer in patients with a negative fFN immunoassay.

引用

页码：257 / 261

页数：5

共 14 条

[1]

Morrison J., Preterm Birth: A Puzzle Worth Solving, Obstet Gynecol, 76, pp. 5S-10S, (1990)

[2]

Creasy R., Preterm birth prevention, Where are we? Am J Obstet Gynecol, 168, pp. 1223-1230, (1993)

[3]

Tucker JM, Goldenberg RL, Davis RO, Copper RL, Winkler CL, Hauth JC., Etiologies of preterm birth in an indigent population: Is prevention a logical expectation?, Obstet Gynecol, 77, pp. 343-347, (1991)

[4]

McLean M, Walters WAW, Smith R., Prediction and early diagnosis of preterm labour. A critical review, Obstet Gynecol Surv, 48, pp. 209-225, (1993)

[5]

Hess LW, O'Brien WF, Holmberg JA, Winkel CA, Monaghan WP, Hemming VG., Plasma and amniotic fluid concentrations of fibronectin during normal pregnancy, Obstet Gynecol, 68, pp. 25-28, (1986)

[6]

Matsuura H, Takio K, Titani K, Et al., The oncofetal structure of human fibronectin defined by monoclonal antibody FDC‐6, J Biol Chem, 263, pp. 3314-3322, (1988)

[7]

Lockwood CJ, Senyei AE, Dische MR, Et al., Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery, N Engl J Med, 325, pp. 669-674, (1991)

[8]

Eriksen NL, Paris! VM, Daoust S, Flamm B, Garite TJ, Cox SM., Fetal fibronectin: A method for detecting the presence of amniotic fluid, Obstet Gynecol, 80, pp. 451-454, (1992)

[9]

Morrison J., Oncofetal fibronectin in patients with fake labour as a predictor of preterm delivery, Am J Obstet Gynecol, 168, pp. 538-542, (1993)

[10]

Nageotte MP, Hollenback KA, Vanderwahl BA, Hutch KM., Oncofetal fibronectin in patients at increased risk for preterm delivery [abstract], Am J Obstet Gynecol, 166, (1992)

← 1 2 →